TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26875198
Drug: Imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imatinib mesylate 400 mg tablets (test formulation)
Study: 26317782
Drug: Hydrocortisone (HC)
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone (HC) at doses of 6 mg/m2/d, 10 mg/m2/d, and 14 mg/m2/d administered thrice daily.
Study: 27265844
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone gel (TRT, n = 20)
Study: 23695200
Drug: Short-term treatment
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term treatment with 40 mg of prednisone daily for 5 days
Study: 8312826
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with zidovudine (AZT) and dideoxycytidine (ddC)
Study: 23695200
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment with 40 mg of prednisone daily for 14 days
Study: 29660425
Drug: Etanercept 50
Normalized name: etanercept 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 50 mg twice weekly for 12 weeks
Study: 28784554
Drug: Ab interno
Normalized name: Crotalidae immune F(ab')2 Injection [Anavip]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ab interno gelatin stent (XEN 45 Gel Stent)
Study: 30926104
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (orthodontic treatment only)
Study: 24334179
Drug: Crofelemer 125
Normalized name: crofelemer 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crofelemer 125 mg twice daily
Study: 19858812
Drug: Interprofessional team
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interprofessional team care (primary care internal medicine residents, nurse practitioner students, pharmacy students)
Study: 25703961
Drug: Riociguat up
Normalized name: Riociguat
DrugBank: Riociguat (DB08931)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Riociguat up to 2.5 mg 3 times daily
Study: 18516002
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (intravenous and oral placebo)
Study: 16242376
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of hypertonic saline into the lumbar multifidus muscle
Study: 16751657
Drug: Dexamethasone 10
Normalized name: dexamethasone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 10 mg per day for 1 day (Group B)
Study: 12543995
Drug: Home-delivered physical
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home-delivered physical and occupational therapy (PT), n = 26, no supervised exercise
Study: 18498921
Drug: Doripenem 500
Normalized name: doripenem 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doripenem 500 mg q8h i.v. (4-hour infusion)
Study: 21444712
Drug: FV-100 100
Normalized name: HORSERADISH 10 g in 100 mL TOPICAL LIQUID [NWK A-FV]
Approvals — FDA: no, EMA: no, PMDA: no
Description: FV-100 100 mg once daily (QD) for 7 days
Study: 21444712
Drug: FV-100 400
Normalized name: HORSERADISH 10 g in 100 mL TOPICAL LIQUID [NWK A-FV]
Approvals — FDA: no, EMA: no, PMDA: no
Description: FV-100 400 mg QD for 7 days
Study: 10905488
Drug: IGF-I treatment
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: IGF-I treatment (40 microg x kg(‐1) x day(‐1))
Study: 10667623
Drug: No oral
Normalized name: Beano Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No oral support (control group)
Study: 18245406
Drug: Sterile water
Normalized name: sterile water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile water control solution
Study: 15789278
Drug: Biphasic human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biphasic human insulin (BHI30)
Study: 19395466
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg granisetron
Study: 16372518
Drug: Zinc oxide
Normalized name: Zinc Oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc oxide (17.4 mg metal zinc)
Study: 6960390
Drug: PGE2 0.5
Normalized name: PGE2 0.5 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGE2 0.5 mg three times daily and 1 mg at night
Study: 17460371
Drug: telmisartan 80
Normalized name: telmisartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: telmisartan 80 mg/day
Study: 9744490
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate 160 mg
Study: 25420897
Drug: Racotumomab-alum vaccine
Normalized name: alum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Racotumomab-alum vaccine
Study: 23337183
Drug: Self-help Acceptance
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-help Acceptance and Commitment Therapy (ACT) with e-mail support
Study: 31397943
Drug: bleselumab 200
Normalized name: Bleselumab
DrugBank: Bleselumab (DB15253)
Approvals — FDA: no, EMA: no, PMDA: no
Description: bleselumab 200 mg
Study: 20140619
Drug: Short-term therapy
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term therapy (4 days)
Study: 26321708
Drug: Longer treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Longer treatment period of sorafenib
Study: 7963139
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C supplementation (100 or 600 mg daily for 58 days)
Study: 29162361
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose tolerance tests (OGTTs) with 25, 75, and 125 g glucose
Study: 16194311
Drug: Glutamine granules
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine granules (0.5 g.kg(‐1).d(‐1) for 7 days)
Study: 30795492
Drug: Risperidone adjunct
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone adjunct therapy for 52 weeks
Study: 2653395
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium slow release (DSR) 100 mg daily
Study: 20634296
Drug: Urinary Albumin
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary Albumin Excretion (UAE)
Study: 20634296
Drug: Urinary Protein
Normalized name: Urinary protein of low molecular weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary Protein Excretion (UPE)
Study: 9653702
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment, next IVF-ET performed within six months after previous failed cycle)
Study: 8138680
Drug: E5 (edobacomab)
Normalized name: HYDROXYPROPYL METHYLCELLULOSE E5 [II]
DrugBank: Edobacomab (DB17779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: E5 (edobacomab) 1 mg/kg
Study: 25216712
Drug: Sunflower oil
Normalized name: Sunflower Oil
DrugBank: Sunflower oil (DB14329)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunflower oil (linoleic acid; 10 g LA/day)
Study: 11421189
Drug: Supervised physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised physical therapy rehabilitation (one hour, twice weekly) with emphasis on balance training
Study: 9402175
Drug: Second-line treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-line treatment for relapsing patients
Study: 10928578
Drug: Gabapentin 3600
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin 3600 mg per day
Study: 15184611
Drug: Natalizumab 3
Normalized name: natalizumab 300 MG in 15 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natalizumab 3 mg/kg
Study: 10102948
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg once daily for 2 weeks
Study: 28805601
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptive pills (COC) containing 30 μg of EE and 3 mg of drospirenone for 12 consecutive cycles
Study: 1095098
Drug: 200 rads
Normalized name: RAD-IFN
DrugBank: Nadofaragene firadenovec (DB17381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 rads daily five times weekly for four weeks
Study: 24298762
Drug: Theophylline sustained
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline sustained release tablet combined with oxygen uptake, aerosol inhalation, and oral administration of prednisone
Study: 19967563
Drug: n-3 fatty
Normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 fatty acids (900 mg per day for 6 months)
Study: 16109326
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 48 mg/min
Study: 15073669
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg famciclovir 3 times daily
Study: 9380326
Drug: Oral beta
Normalized name: Cloral betaine
DrugBank: Chloral betaine (DB01494)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral beta carotene for at least 6 months
Study: 17309456
Drug: Ketoconazole 2%
Normalized name: KETOCONAZOLE 2% CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole 2% cream
Study: 8884758
Drug: Alprazolam (APZ)
Normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alprazolam (APZ) 1 mg/day orally for 3 days
Study: 7688774
Drug: Capsaicin 0.025%
Normalized name: CAPSAICIN 0.025% CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsaicin 0.025% cream
Study: 30592353
Drug: Cardiac resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac resynchronization therapy with defibrillator (CRT-D)
Study: 23135345
Drug: Teriparatide 20
Normalized name: TERIPARATIDE 200UNT/VIL INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide 20 μg/day
Study: 27422279
Drug: 9vHPV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9vHPV vaccine
Study: 9631991
Drug: Fluconazole 450
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole 450 mg once weekly for 4 months
Study: 9631991
Drug: Fluconazole 450
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole 450 mg once weekly for 6 months
Study: 15152493
Drug: Antiplatelet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet therapy (low dose aspirin 75 to 150 mg)
Study: 17526461
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (500 mg)
Study: 18471515
Drug: IC41 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IC41 vaccine (3 different dose groups)
Study: 21709132
Drug: Health care
Normalized name: Health Care Lancing Device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health care providers' written prescriptions for physical activity without additional physical activity resources
Study: 28754306
Drug: Deep Brain
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep Brain Stimulation (DBS) of the ventral anterior limb of the internal capsule (vALIC)
Study: 12947997
Drug: Injection immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection immunotherapy
Study: 27410922
Drug: Olanzapine 10
Normalized name: olanzapine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 10 mg orally daily on days 1 through 4
Study: 3653766
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cyclophosphamide, doxorubicin, and cisplatin (CAP) 400 mg/m2, 40 mg/m2, and 40 mg/m2 respectively every 4 weeks
Study: 24712573
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (50,000 IU weekly for 8 weeks)
Study: 23124178
Drug: Solution-Focused Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution-Focused Therapy (SFT)
Study: 22971528
Drug: Cupping therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cupping therapy
Study: 24612661
Drug: Celecoxib added
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib added to standard treatment
Study: 24868083
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose combination treatment
Study: 12121563
Drug: Low-dose meglumine
Normalized name: Meglumine
DrugBank: Meglumine (DB09415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-dose meglumine antimoniate (MA) at 60 mg/kg/day for 20 days
Study: 23070803
Drug: Quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine XR (50-300 mg/day)
Study: 17458428
Drug: Delayed bronchial
Normalized name: Bronchitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delayed bronchial and patch response
Study: 11506402
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone
Study: 2213104
Drug: Combined chemo-endocrine
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined chemo-endocrine therapy (initial treatment)
Study: 26605507
Drug: Live varicella
Normalized name: varicella, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live varicella zoster vaccine
Study: 27716159
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection (20 mg Depo-Medrone)
Study: 10540058
Drug: Rectal diclofenac
Normalized name: diclofenac Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal diclofenac 100 mg immediately post-induction
Study: 27265181
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein + 3 g HMB (HMB)
Study: 9087387
Drug: Interferon-gamma (IFN-gamma)
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-gamma (IFN-gamma) therapy
Study: 20061838
Drug: Gabapentin monotherapy
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin monotherapy
Study: 21309476
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg plain bupivacaine plus 35 mg meperidine (BM35)
Study: 26361756
Drug: Radial Extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial Extracorporeal Shock Wave Therapy (rESWT) combined with supervised exercises (SE)
Study: 10932511
Drug: Cyproterone acetate
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate 1 mg/day
Study: 17311617
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 1 mg/day for 6 months
Study: 11503945
Drug: Pyridostigmine bromide
Normalized name: Pyridostigmine Bromide
DrugBank: Pyridostigmine (DB00545)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pyridostigmine bromide (30 mg orally)
Study: 11899388
Drug: Paclitaxel 175
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 175 mg/m2 given as a 3-hour infusion every 3 weeks
Study: 11004058
Drug: IV lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV lidocaine (bolus 2 mg/kg, then infusion 3 mg/kg/h)
Study: 1799915
Drug: Cefpodoxime proxetil
Normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefpodoxime proxetil 100 mg orally with food every 12 hours
Study: 1799915
Drug: Penicillin V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin V potassium 250 mg orally on an empty stomach every six hours
Study: 22119995
Drug: Intraperitoneal (IP)
Normalized name: Intraperitoneal Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal (IP) chemotherapy
Study: 21455089
Drug: Thoracic epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic epidural analgesia (TEA) with bupivacaine 1 mg/mL, epinephrine 2 μg/mL, and fentanyl 2 μg/mL
Study: 22930695
Drug: Topical glyceryl
Normalized name: glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical glyceryl trinitrate (GTN) treatment
Study: 16762763
Drug: Anticoagulant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulant treatment for acute PE
Study: 17634183
Drug: Disodium cromoglycate
Normalized name: Disodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disodium cromoglycate (DSCG) 10 mg three times daily for months 1‐18
Study: 16420563
Drug: Pro12Ala polymorphism
Normalized name: ANGELICA POLYMORPHA ROOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pro12Ala polymorphism in the peroxisome proliferator activated-receptor gamma gene
Study: 16420563
Drug: Thr164Ile polymorphism
Normalized name: ANGELICA POLYMORPHA ROOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thr164Ile polymorphism in the beta-2 adrenergic receptor gene
Study: 9409295
Drug: Cyclic oral
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic oral estradiol combined with progesterone
Study: 26945767
Drug: Conventional perioperative
Normalized name: ENSURE SURGERY PERIOPERATIVE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional perioperative antibiotics plus vancomycin and gentamicin injection (twice)
Study: 6788433
Drug: Low doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low doses of factor VIII (7 or 14 units per kg)
Study: 16527796
Drug: NTI under
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NTI under CTSC guidance (G[+] group)
Study: 18067499
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (10 mg/kg ev bolus followed by 1 mg/kg/hour perfusion)
Study: 11707839
Drug: Methotrexate-based chemotherapy
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate-based chemotherapy
Study: 15842446
Drug: Early discharge
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early discharge with nurse follow-up (weekly or biweekly telephone calls)
Study: 21645895
Drug: drospirenone (DRSP)
Normalized name: Drospirenone
DrugBank: Drospirenone (DB01395)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: drospirenone (DRSP) 2 mg + E(2) 1 mg
Study: 9732194
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg piroxicam (2 ml) administered intramuscularly 45 min before ESWL
Study: 31957953
Drug: Low-dose TAS-205
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose TAS-205 (6.67-13.33 mg/kg/dose)
Study: 10984252
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH)
Study: 3955779
Drug: Cefotaxime 2g
DrugBank: Cefotaxime (DB00493)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefotaxime 2g twice daily (1st trial)
Study: 347034
Drug: polyinosinic-polycytidylic acid
Normalized name: Polyinosinic-polycytidylic acid/inactivated rabies virus
DrugBank: YS-ON-001 (DB17291)
Approvals — FDA: no, EMA: no, PMDA: no
Description: polyinosinic-polycytidylic acid (rIn.rCn) at doses of 3-12 mg/kg (Lot 2)
Study: 17497438
Drug: Azithromycin plus
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin plus Oral Hygiene Program (OHP)
Study: 17497438
Drug: Oral Hygiene
Normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Hygiene Program (OHP) alone
Study: 1743245
Drug: Oxazepam 25
Normalized name: Oxazepam 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxazepam 25 mg/d
Study: 31467115
Drug: Inhaled α1-antitrypsin
Normalized name: alpha 1-antitrypsin
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled α1-antitrypsin (AAT)
Study: 2414253
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy without added chemotherapy
Study: 9105542
Drug: Gliquidone 30
Normalized name: gliquidone 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliquidone 30 mg tablet administered 15 min before breakfast
Study: 29738877
Drug: Oral group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral group
Study: 10344062
Drug: Captopril 6.25
Normalized name: captopril 6.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 6.25 mg
Study: 15452681
Drug: Isradipine with
Normalized name: Isradipine
DrugBank: Isradipine (DB00270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isradipine with high dose methamphetamine (30 mg)